If the data will be as good as the ph1 read out or better then...

If the data will be as good as the ph1 read out or better then it could be worth in the USD billions. It all depends on how much better than the current treatments and how quickly it could get FDA approved. Definitely more than what the MC currently is, and that includes CDH 17 and NK-platform.

ALA went again upwards and still not an IND, their MC now 135m, EV 125m, about 12-15x that of CHM's EV. And again, what have they got or achieved?

The difference is a management that is actively persuading investors that their iNKT is the best thing since sliced bread based on pre-clinicals. They target liquid cancers such as blood and skin, an already saturated cell therapy field covering about 10% of all cancers. CHM's NK are in the same group but already great data on the score book and if the current AML trial works out as expected then there is a fast approval possible.

CDH17 targets 90% of all cancers and so far, apart of IMU's CF33 / CD19 combo, there is no direct solid cancer CAR-T out there and CDH17 is about to get into the first patients any day. Again, why is the market considering ALA's 101 as gold and everything CHM got as crap. Doesn't make sense unless someone deliberately talks and CapRaises the company down. Who could that be? Steini?

GLTA